Literature DB >> 27255375

Formulation and evaluation of proniosomes containing lornoxicam.

Jyotsana R Madan1, Nitesh P Ghuge2, Kamal Dua3.   

Abstract

Proniosomes are the new generation provesicular drug delivery system of non-ionic surfactant, lecithin and cholesterol which upon reconstitution get converted into niosomes. The objective of current study was to develop stable and sustain transdermal delivery system for lornoxicam. Lornoxicam-loaded topically applied proniosomal gel was formulated, optimized, and evaluated with the aim to deliver drug transdermally. Lornoxicam-loaded proniosomal gels were prepared that contained Lutrol F68 and lecithin as surfactants, cholesterol as a stabilizer, and minimal amount of ethanol and trace water. The resultant lornoxicam-loaded proniosomal gel were assessed for stability and the proniosomes-derived niosomes were characterized for morphology, size, zeta potential, and entrapment efficiency, which revealed that they were suitable for skin application. The coacervation phase separation technique was used in formulation of lornoxicam proniosomal gel and the gel was further assessed for in vitro permeation of lornoxicam through the freshly excised rat skin and the cumulative permeation amount of lornoxicam from proniosome, all exhibited significant increase as compared to 1.0 % lornoxicam-loaded pure gel. The optimized F5 batch had shown maximum entrapment efficiency up to 66.98 %. It has shown sustained drug release for more than 24 h. The skin permeability of proniosomal gel was found to be 59.73 %. The SEM and zeta potential studies showed formation of good and stable vesicles. Thus, proniosomes proved to have better potential for transdermal delivery of lornoxicam over conventional gel formulations.

Entities:  

Keywords:  Entrapment efficiency; Gel; Lecithin; Lornoxicam; Proniosomes

Mesh:

Substances:

Year:  2016        PMID: 27255375     DOI: 10.1007/s13346-016-0296-9

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  18 in total

1.  In vitro skin permeation of estradiol from various proniosome formulations.

Authors:  J Y Fang; S Y Yu; P C Wu; Y B Huang; Y H Tsai
Journal:  Int J Pharm       Date:  2001-03-14       Impact factor: 5.875

2.  Rheological studies on solid lipid nanoparticle based carbopol gels of aceclofenac.

Authors:  Viney Chawla; Shubhini A Saraf
Journal:  Colloids Surf B Biointerfaces       Date:  2011-12-20       Impact factor: 5.268

3.  Investigation of formulation variables and excipient interaction on the production of niosomes.

Authors:  Zerrin Sezgin-Bayindir; Nilufer Yuksel
Journal:  AAPS PharmSciTech       Date:  2012-05-30       Impact factor: 3.246

Review 4.  Recent advances in colloidal and interfacial phenomena involving liquid crystals.

Authors:  Yiqun Bai; Nicholas L Abbott
Journal:  Langmuir       Date:  2010-11-19       Impact factor: 3.882

5.  Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation.

Authors:  Saritha Alladi; Nalini R Shastri
Journal:  Arch Pharm Res       Date:  2014-04-22       Impact factor: 4.946

6.  Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery.

Authors:  Gamal M El Maghraby; Amal A Ahmed; Mohamed A Osman
Journal:  Saudi Pharm J       Date:  2014-05-12       Impact factor: 4.330

7.  Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection.

Authors:  Qi Li; Zhanrong Li; Weidong Zeng; Shumin Ge; Haoyang Lu; Chuanbin Wu; Li Ge; Dan Liang; Yuehong Xu
Journal:  Eur J Pharm Sci       Date:  2014-06-03       Impact factor: 4.384

8.  Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation.

Authors:  Yasser Shahzad; Qalandar Khan; Talib Hussain; Syed Nisar Hussain Shah
Journal:  Int J Biol Macromol       Date:  2013-07-02       Impact factor: 6.953

9.  Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

Authors:  Prabagar Balakrishnan; Srinivasan Shanmugam; Won Seok Lee; Won Mo Lee; Jong Oh Kim; Dong Hoon Oh; Dae-Duk Kim; Jung Sun Kim; Bong Kyu Yoo; Han-Gon Choi; Jong Soo Woo; Chul Soon Yong
Journal:  Int J Pharm       Date:  2009-04-24       Impact factor: 5.875

10.  Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.

Authors:  Deepak Kumbhar; Preeti Wavikar; Pradeep Vavia
Journal:  AAPS PharmSciTech       Date:  2013-07-02       Impact factor: 3.246

View more
  5 in total

1.  Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.

Authors:  Hiral Shah; Anroop B Nair; Jigar Shah; Praful Bharadia; Bandar E Al-Dhubiab
Journal:  Daru       Date:  2019-01-30       Impact factor: 3.117

2.  Evaluation of in vitro and in vivo anti-urolithiatic activity of silver nanoparticles containing aqueous leaf extract of Tragia involucrata.

Authors:  Vinodhini Velu; Moonjit Das; Arunai Nambi Raj N; Kamal Dua; Himaja Malipeddi
Journal:  Drug Deliv Transl Res       Date:  2017-06       Impact factor: 4.617

3.  Lornoxicam-Loaded Chitosan-Decorated Nanoemulsion: Preparation and In Vitro Evaluation for Enhanced Transdermal Delivery.

Authors:  Rahman Ullah Khan; Shefaat Ullah Shah; Sheikh Abdur Rashid; Faiza Naseem; Kifayat Ullah Shah; Arshad Farid; Khalid Rehman Hakeem; Majid Rasool Kamli; Eman Hillal Althubaiti; Soha A Alamoudi
Journal:  Polymers (Basel)       Date:  2022-05-09       Impact factor: 4.967

Review 4.  Lipid-Based Nanovesicular Drug Delivery Systems.

Authors:  Tania Limongi; Francesca Susa; Monica Marini; Marco Allione; Bruno Torre; Roberto Pisano; Enzo di Fabrizio
Journal:  Nanomaterials (Basel)       Date:  2021-12-14       Impact factor: 5.076

Review 5.  Proniosomes derived niosomes: recent advancements in drug delivery and targeting.

Authors:  Maryam Khatoon; Kifayat Ullah Shah; Fakhar Ud Din; Shefaat Ullah Shah; Asim Ur Rehman; Naz Dilawar; Ahmad Nawaz Khan
Journal:  Drug Deliv       Date:  2017       Impact factor: 6.419

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.